We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the latest close session, Pfizer (PFE - Free Report) was up +1.67% at $28.55. The stock outperformed the S&P 500, which registered a daily gain of 0.72%. Elsewhere, the Dow saw an upswing of 0.48%, while the tech-heavy Nasdaq appreciated by 1.16%.
Shares of the drugmaker witnessed a gain of 5.64% over the previous month, beating the performance of the Medical sector with its loss of 7.29%, and the S&P 500's loss of 4.99%.
The upcoming earnings release of Pfizer will be of great interest to investors. In that report, analysts expect Pfizer to post earnings of $0.77 per share. This would mark a year-over-year decline of 16.3%. Meanwhile, the latest consensus estimate predicts the revenue to be $13.83 billion, indicating a 0.86% increase compared to the same quarter of the previous year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $2.97 per share and revenue of $61.01 billion, indicating changes of -7.76% and -2.51%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Pfizer. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 0.12% rise in the Zacks Consensus EPS estimate. As of now, Pfizer holds a Zacks Rank of #3 (Hold).
With respect to valuation, Pfizer is currently being traded at a Forward P/E ratio of 9.45. Its industry sports an average Forward P/E of 14.97, so one might conclude that Pfizer is trading at a discount comparatively.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 160, finds itself in the bottom 35% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Why Pfizer (PFE) Outpaced the Stock Market Today
In the latest close session, Pfizer (PFE - Free Report) was up +1.67% at $28.55. The stock outperformed the S&P 500, which registered a daily gain of 0.72%. Elsewhere, the Dow saw an upswing of 0.48%, while the tech-heavy Nasdaq appreciated by 1.16%.
Shares of the drugmaker witnessed a gain of 5.64% over the previous month, beating the performance of the Medical sector with its loss of 7.29%, and the S&P 500's loss of 4.99%.
The upcoming earnings release of Pfizer will be of great interest to investors. In that report, analysts expect Pfizer to post earnings of $0.77 per share. This would mark a year-over-year decline of 16.3%. Meanwhile, the latest consensus estimate predicts the revenue to be $13.83 billion, indicating a 0.86% increase compared to the same quarter of the previous year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $2.97 per share and revenue of $61.01 billion, indicating changes of -7.76% and -2.51%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Pfizer. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 0.12% rise in the Zacks Consensus EPS estimate. As of now, Pfizer holds a Zacks Rank of #3 (Hold).
With respect to valuation, Pfizer is currently being traded at a Forward P/E ratio of 9.45. Its industry sports an average Forward P/E of 14.97, so one might conclude that Pfizer is trading at a discount comparatively.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 160, finds itself in the bottom 35% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.